![Lynn Seely](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lynn Seely
Amministratore Delegato presso
LYELL IMMUNOPHARMA, INC.
Patrimonio netto: 1 M $ in data 31/05/2026
Profilo
Lynn Seely is President & Chief Executive Officer at Lyell Immunopharma, Inc. since 2026.
Former roles include Chief Executive Officer at Myovant Sciences, Inc. from 2019 to 2020; President, Chief Executive Officer & Director at Myovant Sciences Ltd. from 2016 to 2021; Associate Director-Clinical Development at Chiron Corp.
from 1996 to 2000; Lead Independent Director at Blueprint Medicines Corp.
from 2016 to 2025; Director at Roivant Sciences GmbH; Chief Medical Officer at Orion Acquisition Corp.
II in 2005; Vice President-Clinical Development at Anesiva, Inc. from 2002 to 2005; Vice President-Clinical Development at Pro-Duct Health, Inc. from 2000 to 2001; Faculty Member at the University of California San Diego from 1992 to 1996; Chief Medical Officer & Senior Vice President at Medivation LLC (California) from 2009 to 2015; Vice President-Clinical Development at Cytyc Health Corp.
from 2001 to 2002; Vice President-Clinical Development at Corgentech, Inc. in 2005; Chief Resident-Internal Medicine at Yale School of Medicine.
Education includes an undergraduate degree from the University of Oklahoma in 1981 and a doctorate from the University of Oklahoma College of Medicine in 1985.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 11/05/2026 | 73.878 ( 0,32% ) | 1 M $ | 31/05/2026 |
Posizioni attive di Lynn Seely
| Società | Posizione | Inizio |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Amministratore Delegato | 15/12/2022 |
Precedenti posizioni note di Lynn Seely
| Società | Posizione | Fine |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Direttore/Membro del Consiglio | 17/07/2025 |
| MYOVANT SCIENCES LTD. | Amministratore Delegato | 01/01/2021 |
Myovant Sciences, Inc.
 Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for women''s health and prostate cancer | Amministratore Delegato | 04/01/2020 |
| MEDIVATION INC | Direttore Tecnico/Scientifico/R&S | 15/10/2015 |
Orion Acquisition Corp. II
 Orion Acquisition Corp. II Financial ConglomeratesFinance Development stage company | Direttore Tecnico/Scientifico/R&S | 29/06/2005 |
Formazione di Lynn Seely
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
77
Relazioni di 1° grado
16
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 16 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Orion Acquisition Corp. II
Orion Acquisition Corp. II Financial ConglomeratesFinance Development stage company | Finance |
Anesiva, Inc.
 Anesiva, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for pain management | Health Technology |
Pro-Duct Health, Inc.
 Pro-Duct Health, Inc. Medical SpecialtiesHealth Technology Develops medical products for the evaluation of breast cancer | Health Technology |
University of California San Diego
 University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oklahoma
 University of Oklahoma Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medivation LLC (California)
 Medivation LLC (California) Pharmaceuticals: MajorHealth Technology Engages in the development of novel small molecule drugs to treat serious diseases | Health Technology |
Cytyc Health Corp. | |
Corgentech, Inc.
 Corgentech, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
University of Oklahoma College of Medicine
 University of Oklahoma College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale School of Medicine
 Yale School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roivant Sciences GmbH
 Roivant Sciences GmbH Pharmaceuticals: MajorHealth Technology Develops and markets biopharmaceutical products | Health Technology |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Develops therapeutics for women''s health and prostate cancer | Health Technology |
Myovant Sciences Ltd.
 Myovant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides women's health and prostate cancer solutions | Health Technology |
Lyell Immunopharma, Inc.
 Lyell Immunopharma, Inc. BiotechnologyHealth Technology Develops cell-based immunotherapies for human diseases | Health Technology |
